REVIVA PHARMA HLDGS INC
RVPH
RVPH was delisted on the 13th of May, 2026.
15 hedge funds and large institutions have $4.68M invested in REVIVA PHARMA HLDGS INC in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 2 closing their positions.
820% more call options, than puts
Call options by funds: $230K | Put options by funds: $25K
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
15% more funds holding
Funds holding: 13 → 15 (+2)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
0.31% less ownership
Funds ownership: 0.93% → 0.63% (-0.31%)
38% less capital invested
Capital invested by funds: $7.54M → $4.68M (-$2.87M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$27.9K |
| 2 |
Renaissance Technologies
New York
|
+$25.3K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$5.83K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$2.67K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.23K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$2.04M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$57.7K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6.74K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$6K |
| 5 |
BlackRock
New York
|
-$3.99K |
RVPH Hedge Fund Activity: Q1 2022 in Review
15 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in REVIVA PHARMA HLDGS INC (RVPH) for Q1 2022, worth a combined $4.68M — down 38% from $7.54M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new RVPH positions and 2 closed out — a net gain of 2 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Raymond James & Associates, opening a new position worth an estimated $27.9K. The largest seller was Armistice Capital, exiting entirely with an estimated $2.04M sold.
- 15 institutional investors held REVIVA PHARMA HLDGS INC (RVPH) as of Q1 2022, up from 13 in Q4 2021.
- Funds reported $4.68M of REVIVA PHARMA HLDGS INC stock for Q1 2022, down 38% quarter-over-quarter.
- 4 funds opened new REVIVA PHARMA HLDGS INC positions in Q1 2022 and 2 closed out, a net change of +2 holders.
- The largest REVIVA PHARMA HLDGS INC buyer in Q1 2022 was Raymond James & Associates, an estimated $27.9K added.
- The largest REVIVA PHARMA HLDGS INC seller in Q1 2022 was Armistice Capital, an estimated $2.04M sold.
Based on aggregated 13F filings for Q1 2022.